期刊文献+

大鼠离体肾脏灌流模型在筛选慢性肾病药物的初步应用

Pilot Application of Isolated Perfused Chronic Kidney Transgenic Rat Kidney Model for Discovery and Evaluation of Chronic Kidney Disease Drug
下载PDF
导出
摘要 目的在慢性肾病(CKD)转基因大鼠建立大鼠离体肾脏灌流(IPK)模型,为CKD药物药效学研究提供可靠的工具。方法在患有CKD的转基因大鼠(n=7)建立稳定的IPK模型后,灌流1μmol/L环孢素A(CysA)60min,与未灌流CysA前相比,检测尿液中白蛋白含量的变化。同时,通过CKD转基因大鼠(n=5)体内实验,连续灌胃给药20 mg/kg CysA 15日,验证CysA改变尿液中白蛋白水平的作用。结果用1μmol/L的CysA灌流7只患有CKD的转基因大鼠60 min后显示,CysA具有显著的降低白蛋白尿水平的作用。体内药效学实验,连续灌胃给药20mg/kgCysA15日后,CysA也具有显著的降低白蛋白尿水平的作用。结论 CysA在IPK模型和体内药效学实验结果一致,成功地建立CKD转基因大鼠IPK模型,该模型可作为CKD药物药效学研究的工具。 Objective To establish isolated perfused kidney (IPK) model in chronic kidney disease (CKD) transgenic rat, as a screening tool for CKD drug. Method Seven CKD transgenic rats were perfused with l gmol/L CysA for 60 minutes, the content of albumin in urine were detected before and after treatment to evaluate the effect of CysA. Five CKD transgenic rats were treated with 20 mg/kg CysA/day for 15 days, the content of albumin in urine were compared to 5 control CKD transgenic rats to evaluate in vivo effect of CysA. Results After perfusing 1 gmol/L CysA for 60 minutes, the content of albumin in urine were decrease signicantly. In in vivo efficacy study,after dosing CysA 15days, the content of albumin in urine were also decrease signicantly. Conclusion The consistency of CysA efficacy of decreasing the content of albumin in urine bewteen IPK model and in vivo animal model in CKD transgenic rat is good. The IPK model on CKD transgenic rat have potential to be a further screening tool for CKD drug.
作者 傅婷婷 刘艳
出处 《实验动物与比较医学》 CAS 2017年第5期357-362,共6页 Laboratory Animal and Comparative Medicine
关键词 离体肾脏灌流(IPK) 环孢素A(CysA) 慢性肾病(CKD) Isolated perfused kidney(IPK) Cyclosporin A (CysA) Chronic kidney disease (CKD)
  • 相关文献

参考文献1

二级参考文献19

  • 1[1]Taft D R.The isolated perfused rat kidney model:a useful tool for drug discovery and development[J].Curr Drug Discov Technol,2004,1(1):97 -111. 被引量:1
  • 2[2]Wang J,Nation R L,Evans A M,et al.Isolated rat kidney perfused with dextran and bovine serum albumin:a stable model for investigating renal drug handling[J].J Pharmacol Toxicol Methods,2004,49(2):105-13. 被引量:1
  • 3[3]Lepsy C S,Guttendorf R J,Kugler A R,et al.Effects of organic anion,organic cation,and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney[J].Antimicrob Agents Chemother,2003,47(2):689 -96. 被引量:1
  • 4[4]Johnson R J,Kang D H,Feig D,et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease[J]? Hypertension,2003,41(6):1183 -90. 被引量:1
  • 5[5]Schachter M.Uric acid and hypertension[J].Curr Pharm Des,2005,11(32):4139 -43. 被引量:1
  • 6[6]Kato M,Hisatome I,Tomikura Y,et al.Status of endothelial dependent vasodilation in patients with hyperuricemia[J].Am J Cardiol,2005,96 (11):1576-8. 被引量:1
  • 7[7]Kang D H,Nakagawa T,Feng L,et al.A role for uric acid in the progression of renal disease[J].J Am Soc Nephrol,2002,13(12):2888 -97. 被引量:1
  • 8[8]Poola N R,Bhuiyan D,Ortiz S,et al.A novel HPLC assay for pentamidine:comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney[J].J Pharm Pharm Sci,2002,5(2):135 -45. 被引量:1
  • 9[9]Kanellis J,Kang D H.Uric acid as a mediator of endothelial dysfunction,inflammation,and vascular disease[J].Semin Nephrol,2005,25(1):39-42. 被引量:1
  • 10[10]Sanchez-Lozada L G,Nakagawa T,Kang D H,et al.Hormonal and cytokine effects of uric acid[J].Curr Opin Nephrol Hypertens,2006,15(1):30-3. 被引量:1

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部